ClinicalTrials.Veeva

Menu
R

Rare Disease Research, LLC | Atlanta, GA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

EDG-5506
Ecopipam
Risdiplam
GTX-102
Ataluren
Galcanezumab
Vesleteplirsen
SRP-5051
WVE-210201
Pamrevlumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

34 of 60 total trials

A Phase 2b Study of Zagociguat in Patients With MELAS (PRIZM)

PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral z...

Not yet enrolling
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Drug: zagociguat 15mg
Drug: Placebo

HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a ce...

Enrolling
Genetic Diseases, X-Linked
Muscular Diseases
Biological: CAP-1002
Biological: Placebo

The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy includ...

Enrolling
Duchenne Muscular Dystrophy
Drug: EDG-5506 Dose 3
Drug: EDG-5506 Dose 1

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Enrolling
Chronic Migraine
Drug: Placebo
Drug: Galcanezumab

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling
Episodic Migraine
Drug: Galcanezumab
Drug: Placebo

The main aim of the study is to determine if SHP611 given by injection into the spinal fluid that surrounds the brain and spinal cord (intrathecal; I...

Active, not recruiting
Metachromatic Leukodystrophy (MLD)
Drug: SHP611

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant i...

Enrolling
Prader-Willi Syndrome
Drug: Pitolisant tablet
Other: Placebo tablet

The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment.Participants will re...

Active, not recruiting
Dravet Syndrome (DS)
Epilepsy
Drug: Soticlestat

The primary objective of the study is to evaluate the safety and tolerability of multiple-ascending doses of GTX-102 administered by intrathecal (IT)...

Active, not recruiting
Angelman Syndrome
Drug: GTX-102

This study will be comprised of 2 parts: Part 1 (dose escalation) will be conducted to evaluate the safety and tolerability of 2 doses (100 milligram...

Active, not recruiting
Muscular Dystrophy, Duchenne
Drug: Eteplirsen

The primary objective of this study is to evaluate motor function following treatment with HD nusinersen in participants with spinal muscular atrophy...

Enrolling
Spinal Muscular Atrophy
Drug: Nusinersen

The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[...

Enrolling
Tourette Syndrome
Drug: Ecopipam

This trial will study the efficacy and safety of taldefgrobep alfa as an adjunctive therapy for participants who are already taking a stable dose of...

Active, not recruiting
Neuromuscular Diseases
SMA
Drug: Placebo
Drug: taldefgrobep alfa

This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol administered as ZYN00...

Enrolling
Fragile X Syndrome
Drug: Placebo
Drug: ZYN002 - transdermal gel

This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults...

Enrolling
Tourette Disorder
Drug: Ecopipam Hydrochloride

The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of singl...

Enrolling
Phenylketonuria
Drug: Placebo Tablet
Drug: JNT-517 Suspension

The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)

Invitation-only
Angelman Syndrome
Drug: GTX-102

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based...

Enrolling
Spinal Muscular Atrophy
Drug: Risdiplam

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolesc...

Enrolling
Acute Treatment of Migraine
Drug: Rimegepant / BHV3000

Trial sponsors

Edgewise Therapeutics logo
E
Sarepta Therapeutics logo
PTC Therapeutics logo
Ultragenyx logo
AbbVie logo
A
C
FibroGen logo
Genentech logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems